Document Detail

Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.
MedLine Citation:
PMID:  24902977     Owner:  NLM     Status:  In-Data-Review    
Acute coronary syndromes (ACS) constitute a spectrum of clinical presentations ranging from unstable angina and non-ST-segment elevation myocardial infarction to ST-segment myocardial infarction. Myocardial ischemia in this context occurs as a result of an abrupt decrease in coronary blood flow and resultant imbalance in the myocardial oxygen supply-demand relationship. Coronary blood flow is further compromised by other mechanisms that increase coronary vascular resistance or reduce coronary driving pressure. The goals of treatment are to decrease myocardial oxygen demand, increase coronary blood flow and oxygen supply, and limit myocardial injury. Treatments are generally divided into disease-modifying agents or interventions that improve hard clinical outcomes and other strategies that can reduce ischemia. In addition to traditional drugs such as β-blockers and inhibitors of the renin-angiotensin-aldosterone system, newer agents have expanded the number of molecular pathways targeted for treatment of ACS. Ranolazine, trimetazidine, nicorandil, and ivabradine are medications that have been shown to reduce myocardial ischemia through diverse mechanisms and have been tested in limited fashion in patients with ACS. Attenuating the no-reflow phenomenon and reducing the injury compounded by acute reperfusion after a period of coronary occlusion are active areas of research. Additionally, interventions aimed at ischemic pre- and postconditioning may be useful means by which to limit myocardial infarct size. Trials are also underway to examine altered metabolic and oxygen-related pathways in ACS. This review will discuss traditional and newer anti-ischemic therapies for patients with ACS, exclusive of revascularization, antithrombotic agents, and the use of high-intensity statins.
Victor Soukoulis; William E Boden; Sidney C Smith; Patrick T O'Gara
Related Documents :
24595937 - Is there a relationship between acute coronary syndrome and prostate specific antigen l...
18729077 - Beneficial effects of prolonged systemic administration of plgf on late outcome of post...
6323097 - Equilibrium radionuclide ventriculography in men after transmural myocardial infarction.
8149677 - I-123 metaiodobenzylguanidine--thallium-201 mismatch following myocardial infarction.
1598117 - Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with ...
7446417 - Modification of ventricular tachycardia by procainamide in patients with coronary arter...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Circulation research     Volume:  114     ISSN:  1524-4571     ISO Abbreviation:  Circ. Res.     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-06-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0047103     Medline TA:  Circ Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1944-58     Citation Subset:  IM    
Copyright Information:
© 2014 American Heart Association, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiplatelet and anticoagulation therapy for acute coronary syndromes.
Next Document:  Global perspective on acute coronary syndrome: a burden on the young and poor.